Boormans JL - Search Results

1

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.

Rijnders M, Nakauma-González JA, Robbrecht DGJ, Gil-Jimenez A, Balcioglu HE, Oostvogels AAM, Aarts MJB, Boormans JL, Hamberg P, van der Heijden MS, Szabados BE, van Leenders GJLH, Mehra N, Voortman J, Westgeest HM, de Wit R, van der Veldt AAM, Debets R, Lolkema MP. Rijnders M, et al. Among authors: boormans jl. Nat Commun. 2024 Feb 14;15(1):1349. doi: 10.1038/s41467-024-45714-0. Nat Commun. 2024. PMID: 38355607 Free PMC article.

2

Carcinoma of the sigmoid presenting as a right inguinal hernia.

Boormans JL, Hesp WL, Teune TM, Plaisier PW. Boormans JL, et al. Hernia. 2006 Mar;10(1):93-6. doi: 10.1007/s10029-005-0019-5. Epub 2005 Aug 17. Hernia. 2006. PMID: 16132189

3

Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer.

Boormans JL, Porkka K, Visakorpi T, Trapman J. Boormans JL, et al. Eur Urol. 2011 Jul;60(1):183-4. doi: 10.1016/j.eururo.2011.03.028. Epub 2011 Mar 29. Eur Urol. 2011. PMID: 21474234 No abstract available.

4

Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.

Boormans JL, Wildhagen MF, Bangma CH, Verhagen PC, van Leenders GJ. Boormans JL, et al. BJU Int. 2008 Dec;102(11):1589-93. doi: 10.1111/j.1464-410X.2008.07904.x. Epub 2008 Aug 14. BJU Int. 2008. PMID: 18710447

5

E17K substitution in AKT1 in prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. Boormans JL, et al. Br J Cancer. 2010 May 11;102(10):1491-4. doi: 10.1038/sj.bjc.6605673. Epub 2010 Apr 20. Br J Cancer. 2010. PMID: 20407443 Free PMC article.

6

No evidence of FGFR3 mutations in prostate cancer.

Zuiverloon TC, Boormans JL, Trapman J, van Leenders GJ, Zwarthoff EC. Zuiverloon TC, et al. Among authors: boormans jl. Prostate. 2011 May;71(6):637-41. doi: 10.1002/pros.21279. Epub 2010 Oct 18. Prostate. 2011. PMID: 20957671

7

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J. van Leenders GJ, et al. Among authors: boormans jl. Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15. Mod Pathol. 2011. PMID: 21499236 Free article.

8

Down-staging (<pT2) of urothelial cancer at cystectomy after the diagnosis of detrusor muscle invasion (pT2) at diagnostic transurethral resection (TUR): is prediction possible?

Beukers W, Meijer T, Vissers CJ, Boormans JL, Zwarthoff EC, van Leenders GJ. Beukers W, et al. Among authors: boormans jl. Virchows Arch. 2012 Aug;461(2):149-56. doi: 10.1007/s00428-012-1277-0. Epub 2012 Jul 10. Virchows Arch. 2012. PMID: 22777576 Free PMC article.

9

Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.

Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders GJ, de Vos CV, Jenster G, Trapman J. Boormans JL, et al. Int J Cancer. 2013 Jul 15;133(2):335-45. doi: 10.1002/ijc.28025. Epub 2013 Feb 12. Int J Cancer. 2013. PMID: 23319146 Free article.

10

Attenuated XPC expression is not associated with impaired DNA repair in bladder cancer.

Naipal KA, Raams A, Bruens ST, Brandsma I, Verkaik NS, Jaspers NG, Hoeijmakers JH, van Leenders GJ, Pothof J, Kanaar R, Boormans J, van Gent DC. Naipal KA, et al. PLoS One. 2015 Apr 30;10(4):e0126029. doi: 10.1371/journal.pone.0126029. eCollection 2015. PLoS One. 2015. PMID: 25927440 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

131 results

Search Page